Skip to main content

Janus Henderson Investors — Portfolio, Page 7

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

227
Companies
$31.3B
Total invested
$160.4M
Avg. check
19
Industries
Biotechnology 20Therapeutics 15Health Care 12Life Science 9Medical 7Biopharma 5+13 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 145168 of 227
Ocugen
January 2026

Ocugen is a biotechnology company that develops novel gene and cell therapies to improve health and patient outcomes.

Biopharma · Malvern$22.5M Post Ipo Equity
Think Bioscience
January 2026

Think Bioscience is reimagining synthetic biology by guiding the design and assembly of better medicines through the use of living systems.

Biotechnology · Boulder$55.0M Series A
Diagonal Therapeutics
January 2026

Diagonal Therapeutics is a biotechnology startup that develops targeted therapies for cancer and genetic diseases.

Biopharma · Watertown$125.0M Series B
Starlab Space
January 2026

Developing the next-generation, AI-enabled commercial space station

Aerospace · WebsterSeries Unknown
CAMP4 Therapeutics
December 2025

CAMP4 Therapeutics is a biotechnology company that uses RNA to restore healthy gene expression.

Biopharma · Cambridge$30.0M Post Ipo Equity
Yarrow
December 2025

Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease.

Business Intelligence · New York$200.0M Series Unknown
Jade Biosciences
December 2025

Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications.

Health Care · Waltham$45.0M Post Ipo Equity
Ambros Therapeutics
December 2025

Ambros Therapeutics is a clinical-stage biotechnology company.

Biotechnology · Irvine$125.0M Series A
Kymera Therapeutics
December 2025

Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.

Biotechnology · Cambridge$602.0M Post Ipo Equity
BlossomHill Therapeutics
December 2025

BlossomHill Therapeutics is a biopharmaceutical company focusing on oncology and autoimmune disorders.

Biopharma · San Diego$84.0M Series B
Structure Therapeutics
December 2025

Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.

Biotechnology · South San Francisco$747.5M Post Ipo Equity
Nuvalent
November 2025

Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer.

Biotechnology · Cambridge$500.0M Post Ipo Secondary
Artios Pharma
November 2025

Artios Pharma is a biopharmaceutical company that provides new solutions in the DNA damage response (DDR) field.

Biopharma · Cambridge$115.0M Series D
Bambusa Therapeutics
November 2025

Bambusa Therapeutics operates as biotechnology company.

Biotechnology · BostonSeries A
Annexon Biosciences
November 2025

Annexon Biosciences is a biotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders.

Biotechnology · South San Francisco$86.3M Post Ipo Equity
Centessa Pharmaceuticals
November 2025

Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process.

Biotechnology · Cambridge$250.0M Post Ipo Equity
4D Molecular Therapeutics
November 2025

4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

Biotechnology · Emeryville$100.0M Post Ipo Equity
Sonoma Biotherapeutics
November 2025

Sonoma Biotherapeutics develops engineered regulatory T-cell (Treg) therapies to treat autoimmune and inflammatory diseases.

Biotechnology · South San Francisco$300K Grant
MindMed
October 2025

MindMed provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses.

Biotechnology · New York$225.0M Post Ipo Equity
Tango Therapeutics
October 2025

Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.

Biotechnology · Cambridge$197.0M Post Ipo Equity
Owlet Baby Care
October 2025

Owlet Baby Care offers a health monitor that allows parents to view their child's vital signs in real-time.

Baby · Lehi$30.0M Post Ipo Equity
LEXEO Therapeutics
October 2025

LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.

Biotechnology · New York$154.0M Post Ipo Equity
AtaiBeckley
October 2025

AtaiBeckley develops innovative mental health treatments that address significant unmet medical needs.

Biotechnology · Berlin$149.5M Post Ipo Equity
Tubulis
October 2025

Tubulis generates antibody-drug conjugates with unique properties for solid tumor indications.

Biotechnology · Munich$400.6M Series C

Where Janus Henderson Investors invests

Biotechnology20
Therapeutics15
Health Care12
Life Science9
Medical7
Biopharma5

About Janus Henderson Investors's portfolio

How many companies has Janus Henderson Investors invested in?

Janus Henderson Investors has invested in 227 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Janus Henderson Investors invest in?

Janus Henderson Investors's top investment sectors include Biotechnology, Therapeutics, Health Care, Life Science, Medical. The firm invests across 19 different industry categories.

What is Janus Henderson Investors's largest investment?

Among tracked funding rounds, Structure Therapeutics received $747.5M in a Post Ipo Equity round. Janus Henderson Investors's total known invested capital is $31.3B.

What is the average investment size for Janus Henderson Investors?

Janus Henderson Investors's average investment size is $160.4M across its portfolio of 227 companies.

What are Janus Henderson Investors's most recent investments?

Recent Janus Henderson Investors portfolio additions include Ocugen, Think Bioscience, Diagonal Therapeutics, Starlab Space, CAMP4 Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 227 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →